Education
| School — Major — Degree | Duration |
|---|---|
|
國防醫學院 — 生命科學研究所(畢) — 博士 Doctorate, Graduate Institute of Life Sciences, National Defense Medical Center |
2006/09 — 2012/01 |
|
長庚大學 — 醫學生物技術研究所(畢) — 碩士 Master, Department of Medical Biotechnology and Laboratory Science, Chang Gung University |
2003/09 — 2005/06 |
|
中山醫學大學 — 生命科學系(畢) — 學士 Bachelor, Department of Biomedical Sciences, Chung Shan Medical University |
1999/09 — 2003/06 |
Intramural Experience
| Office/Department/Institute | Position | Duration |
|---|---|---|
| 藥理學科 Department of Pharmacology | Assistant Professor | 2025/08/01 — |
Extramural Experience
| DEPNO | Position- Office/Department/Institute | Duration |
|---|---|---|
| 義大醫院醫學研究部 | 助理研究員 | 1100726 — 1140731 |
| 靜宜大學化粧品科學系 | 約聘助理教授 | 1070801 — 1100725 |
Discipline
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
免疫調節之藥物開發、抗癌藥物開發、腫瘤免疫微環境之致病機轉研究與其藥物開發、改善代謝疾病之保健產品與藥物開發
Research focuses on the development of immunomodulatory and anticancer drugs, investigation of the pathogenic mechanisms of the tumor immune microenvironment and related therapeutic development, as well as the development of health supplements and pharmaceutical agents for metabolic diseases.
Area(s) of Expertise & Research
發炎免疫藥理學、癌症藥理學、天然藥物開發、腫瘤免疫微環境、分子細胞生物學
Inflammation pharmacology; cancer pharmacology; development of natural medicine; tumor immune microenvironment; molecular and cellular biology
Publication
| NO | Publication |
|---|---|
| 1 | Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancer. Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancer. |
| 2 | Unlocking the potential of novel tetrahydro-β-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluation. Unlocking the potential of novel tetrahydro-β-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluation. |
| 3 | Scutellaria barbata ameliorates acute respiratory distress syndrome by inhibiting neutrophil-mediated inflammatory responses. Scutellaria barbata ameliorates acute respiratory distress syndrome by inhibiting neutrophil-mediated inflammatory responses. |
| 4 | Discovery of a novel C2-functionalized chromen-4-one scaffold for the development of p38α MAPK signaling inhibitors to mitigate neutrophilic inflammatory responses. Discovery of a novel C2-functionalized chromen-4-one scaffold for the development of p38α MAPK signaling inhibitors to mitigate neutrophilic inflammatory responses. |
| 5 | Coastal halophyte plant with previously undescribed terpenoids and anti-colorectal cancer chlorophyll stereoisomers utilizing a molecular networking approach. Coastal halophyte plant with previously undescribed terpenoids and anti-colorectal cancer chlorophyll stereoisomers utilizing a molecular networking approach. |
| 6 | Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis |
| 7 | Guizhi Fuling Wan ameliorates concanavalin A-induced autoimmune hepatitis in mice Guizhi Fuling Wan ameliorates concanavalin A-induced autoimmune hepatitis in mice |
| 8 | Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome. Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome. |
| 9 | -Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents. -Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents. |
| 10 | Development of 5-hydroxybenzothiophene derivatives as multi-kinase inhibitors with potential anti-cancer activity. Development of 5-hydroxybenzothiophene derivatives as multi-kinase inhibitors with potential anti-cancer activity. |
| 11 | Palbociclib blocks neutrophilic phosphatidylinositol 3-kinase activity to alleviate psoriasiform dermatitis. Palbociclib blocks neutrophilic phosphatidylinositol 3-kinase activity to alleviate psoriasiform dermatitis. |
| 12 | From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazolinyl)-phenylthiourea derivatives as novel NF-κB inhibitors. From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazolinyl)-phenylthiourea derivatives as novel NF-κB inhibitors. |
| 13 | Lophatherum gracile Brongn. attenuates neutrophilic inflammation through inhibition of JNK and calcium. Lophatherum gracile Brongn. attenuates neutrophilic inflammation through inhibition of JNK and calcium. |
| 14 | Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity. Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity. |
Project
| NO |
YEAR — Source — No — Type
Project Name
|
Duration |
|---|---|---|
| 1 |
115 — N 國科會(原科技部) — NSTC113-2320-B-037-032-MY3 — 1 個人型
探討台灣白及天然物對大腸直腸癌與嗜中性白血球交互作用之影響及其療效評估(3/3)( )
|
2026/08/01 ~ 2027/07/31 |
| 2 |
114 — N 國科會(原科技部) — NSTC113-2320-B-037-032-MY3 — 1 個人型
探討台灣白及天然物對大腸直腸癌與嗜中性白血球交互作用之影響及其療效評估(2/3)( )
|
2025/08/01 ~ 2027/07/31 |
| 3 |
114 — N 國科會(原科技部) — NSTC113-2320-B-037-032-MY3 — 1 個人型
探討台灣白及天然物對大腸直腸癌與嗜中性白血球交互作用之影響及其療效評估(1/3)--義大醫療財團法人義大醫院第一年餘款轉入( )
|
2025/08/01 ~ 2027/07/31 |
| 4 |
114 — Q 新聘教師計畫(校內) — KMU-Q115003 —
改善嗜中性白血球發炎疾病之臨床前藥物開發( )
|
2026/01/01 ~ 2026/12/31 |
| 5 |
114 — Z 大專學生研究計畫及博士後 — NSTC114-2811-B-037-033 — 9 博士後研究員
博士級研究人員--陳俊宏( )
|
2025/08/01 ~ 2026/07/31 |